Form 4: Altimmune Director Sayare Receives Stock Options

Altimmune, Inc. Director Mitchel Sayare was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months starting September 25, 2025.

Summary

• Mitchel Sayare, a Director of Altimmune, Inc. (ALT), was granted 48,800 stock options.
• The options have an exercise price of $3.92 per share.
• The transaction date for the grant was September 25, 2025.
• The options will vest in substantially equal monthly installments over 12 months, beginning September 25, 2025, contingent on continued service.
• The options have an expiration date of September 25, 2035.
• Following this transaction, Mitchel Sayare directly beneficially owns 48,800 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event (stock option grant) for a director, which is generally neutral but can be seen as slightly positive due to incentive alignment. It contains no unexpected positive or negative news regarding company operations or financial performance.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over 12 months encourages continued service and commitment from the director.

Negatives

• Potential future dilution for existing shareholders if the options are exercised, though this is standard for equity compensation.

Risks

• The value of the stock options is subject to the future market price of Altimmune, Inc. common stock, which may fluctuate.
• The vesting of options is contingent on the reporting person's continued service, meaning unvested options could be forfeited if service ceases.

Future Outlook

The granted stock options will vest in substantially equal monthly installments over 12 months following September 25, 2025, subject to the director's continued service through the applicable vesting dates.

Management Comments

• The filing was signed by Gregory Weaver, as Attorney-in-Fact for Mitchel Sayare, on September 29, 2025.

Industry Context

This filing reports a routine equity compensation event for a director, which is a common practice across various industries to align management and board interests with shareholder value. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• N/A. This filing details an individual compensation event and does not contain information suitable for comparison to global industry benchmarks or specific comparable companies/projects.

Corporate Governance

Related Party Transactions

• Grant of 48,800 stock options to Mitchel Sayare, a Director of Altimmune, Inc., which constitutes a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director incentives with shareholder value.
• Director (Mitchel Sayare): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance and continued service.

Next Steps

• The stock options will begin vesting in substantially equal monthly installments over 12 months from September 25, 2025.
• The director must continue service through the vesting dates to receive the shares.

Key Dates

Recommendation

This Form 4 details a routine grant of stock options to a director as part of their compensation package. Such an event is standard practice and does not typically provide new material information that would warrant a change in investment recommendation for a seasoned investor or institution. The core investment thesis for Altimmune, Inc. remains unchanged based on this filing.

Keywords

Altimmune, ALT, Mitchel Sayare, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant